PMID- 32622363
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jul 4
TI  - The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) 
      inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
PG  - 151
LID - 10.1186/s12957-020-01931-7 [doi]
LID - 151
AB  - BACKGROUND: The purpose of this study was to explore the efficacy and 
      tolerability of poly ADP-ribose polymerase (PARP) inhibitors in patients with 
      ovarian cancer. METHODS: The meta-analysis searched the PubMed, Web of Science, 
      EBSCO, and Cochrane libraries from inception to February 2020 to identify 
      relevant studies. And the main results of this study were long-term prognosis and 
      treatment-related adverse events. RESULTS: The results showed that the addition 
      of PARP inhibitors could significantly prolong progression-free survival (PFS) 
      and overall survival (OS) for patients with ovarian cancer (HR 0.44, 95% CI 
      0.34-0.53, p < 0.001; HR, 0.79, 95% CI 0.65-0.94, p < 0.001, respectively). In 
      the BRCA 1/2 mutation patients, the HR of PFS was 0.29 (p < 0.001), and the HR 
      was 0.51 (p < 0.001) in the no BRCA 1/2 mutation patients. The HR of PFS was 0.40 
      (p < 0.001) in the homologous recombination deficiency (HRD) mutation patients, 
      while the HR was 0.80 (p < 0.001) in the no HRD mutation patients. Moreover, the 
      analysis found that the use of PARP inhibitors did not significantly increase the 
      risk of all grade adverse events (AEs) (RR = 1.04, p = 0.16). But the incidence 
      of grade 3 or higher AEs was increased (RR = 1.87, p = 0.002). In general, the 
      AEs were mainly manifested in the blood system. CONCLUSIONS: PARP inhibitors can 
      improve the prognosis of ovarian cancer patients with and without genetic 
      mutations (BRCA 1/2 or HRD). Furthermore, PARP inhibitors were tolerable to 
      patients when added to their current therapy, although it inevitably adds the 
      grade 3 and higher AEs.
FAU - Yang, Yingzhu
AU  - Yang Y
AD  - Department of Gynecology, Ningbo Women and Children's Hospital, Liuting Street 
      339, Haishu District, Ningbo, Zhejiang, 315000, China.
FAU - Du, Nannan
AU  - Du N
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Xie, Laidi
AU  - Xie L
AD  - Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
FAU - Jiang, Jing
AU  - Jiang J
AD  - Department of Gynecology, Ningbo Women and Children's Hospital, Liuting Street 
      339, Haishu District, Ningbo, Zhejiang, 315000, China.
FAU - Mo, Jiahang
AU  - Mo J
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Hong, Jiaze
AU  - Hong J
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Mao, Danyi
AU  - Mao D
AD  - Basic Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 
      China.
FAU - Ng, Derry Minyao
AU  - Ng DM
AD  - Medical College of Ningbo University, Ningbo, Zhejiang, China.
FAU - Shi, Huiwei
AU  - Shi H
AUID- ORCID: 0000-0003-0326-7969
AD  - Department of Gynecology, Ningbo Women and Children's Hospital, Liuting Street 
      339, Haishu District, Ningbo, Zhejiang, 315000, China. shihuiwei000@sina.com.
LA  - eng
GR  - 2018KY716/Medical Health Science and Technology Project of Zhejiang Provincial 
      Health Commission/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20200704
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 20762-30-5 (Adenosine Diphosphate Ribose)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
SB  - IM
MH  - Adenosine Diphosphate Ribose/therapeutic use
MH  - Female
MH  - Humans
MH  - *Ovarian Neoplasms/drug therapy
MH  - *Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
MH  - Poly(ADP-ribose) Polymerases/therapeutic use
MH  - Prognosis
PMC - PMC7335450
OTO - NOTNLM
OT  - BRCA 1/2
OT  - HRD
OT  - Meta-analysis
OT  - Ovarian cancer
OT  - PARP inhibitor
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/07/06 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/07/04
CRDT- 2020/07/06 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/06 06:00 [entrez]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/07/04 00:00 [pmc-release]
AID - 10.1186/s12957-020-01931-7 [pii]
AID - 1931 [pii]
AID - 10.1186/s12957-020-01931-7 [doi]
PST - epublish
SO  - World J Surg Oncol. 2020 Jul 4;18(1):151. doi: 10.1186/s12957-020-01931-7.